Biomerica, Inc. (BMRA), a provider of advanced diagnostic solutions, announced on Thursday that the Egyptian Drug Authority (EDA) has granted authorization for its complete portfolio of rapid tests for conditions related to cancers and chronic diseases.
The approval covers Biomerica's at-home tests, including the EZ Detect Colon Disease Test, Aware Breast Self Exam, Fortel Prostate (PSA) Screening Test, Fortel Kidney Disease Screening Test, and Fortel Ulcer (H. pylori) Screening Test.
Biomerica shares rose more than 4% in pre-market trading, after closing at $2.50, up 1.62% on Wednesday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.